CAPR
Capricor Therapeutics, Inc.
Biotechnology · Healthcare · United States
6.38
close · 2026-10-30
value
76
cheaper than peers76
quality
26
stronger fundamentals26
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | 0.4% | 100 |
| earnings yield, 2 years ago | -13.0% | 69 |
| price to book | 1.51× | 67 |
| earnings yield, 3 years ago | -18.5% | 66 |
| cash flow yield, 2 years ago | -7.5% | 63 |
| earnings yield, 1 year ago | -18.0% | 60 |
| cash flow yield, 1 year ago | -11.2% | 60 |
| cash flow yield, latest year | -22.0% | 43 |
| earnings yield, latest year | -35.4% | 43 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -73.7% | 45 |
| debt to equity | 37.0% | 20 |
3 of 4 measures available
Facts
| market cap | $371M |
| free cash flow | -$89.2M |
| employees | 231 |
| first trade | 2007-02-13 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.26 | -1.15 | -0.83 | -1.18 |
| free cash flow | -$81.5M | -$41.5M | -$27.6M | $1.6M |
| net income | -$105.0M | -$40.5M | -$22.3M | -$29.0M |
| revenue | $0 | $22.3M | $25.2M | $2.6M |
| unusual items | $6.1M | $2.1M | $1.7M | $487,269 |